A. Legal Requirement, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA
Regulation 29A of the Medicines for Human Use (Clinical Trials) Regulations 2004 [Statutory Instrument 2004/1031], as amended by Statutory Instrument 2006/1928, contains a requirement for the notification of “serious breaches” of GCP or the trial protocol:
“29A. (1) The sponsor of a clinical trial shall notify the licensing authority in writing of any serious breach of –
(a) the conditions and principles of GCP in connection with that trial; or
(b) the protocol relating to that trial, as amended from time to time in accordance with regulations 22 to 25, within 7 days of becoming aware of that breach.
(2) For the purposes of this regulation, a “serious breach” is a breach which is likely to effect to a significant degree –
(a) the safety or physical or mental integrity of the subjects of the trial; or
(b) the scientific value of the trial”.
Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency
Clinical Research News
Upcoming Clinical Research Training and Conferences
-
on demandACROSS Global Training AcademyOnline
-
29 September 2023 – 02 October 2024SCDM (Society of Clinical Data Management)United States
-
21 – 23 May 2024InformaBelgium
-
03 – 04 June 2024The Society for Clinical Research Sites (SCRS)United States
-
16 – 17 July 2024The Society for Clinical Research Sites (SCRS)Australia
-
27 September – 29 October 2024The Society for Clinical Research Sites (SCRS)United States
Kommende kliniske forsøg
-
National Institute of Medical Sciences and Nutrition...Ikke rekrutterer endnuRhA - Reumatoid arthritis
-
Institute of Liver and Biliary Sciences, IndiaIkke rekrutterer endnuAkut-på-kronisk leversvigtIndien
-
Centre Leon BerardIkke rekrutterer endnu
-
TC Erciyes UniversityRekrutteringEndodontisk sygdomKalkun
-
Casa di Cura Privata 'Malzoni - Villa dei Platani...Rekruttering
-
Assembly BiosciencesIkke rekrutterer endnuTilbagevendende genital herpes simplex type 2New Zealand
-
Cerenovus, Part of DePuy Synthes Products, Inc.Ikke rekrutterer endnuAkut iskæmisk slagtilfældeForenede Stater
-
Pamukkale UniversityIkke rekrutterer endnuUrinblære, overaktivKalkun
-
China-Japan Friendship HospitalIkke rekrutterer endnuFedme | Diabetes | Galdesten | Biliær Stasis
-
AstraZenecaDaiichi SankyoIkke rekrutterer endnuMetastatisk brystkræft | HER2-positiv brystkræft | Uoprettelig brystkræft | HER2-lav udtrykkende brystkræftCanada
-
Chinese University of Hong KongRekruttering
-
Central Hospital, Nancy, FranceIkke rekrutterer endnu